Charles River Laboratories International, Inc. (NYSE:CRL – Get Free Report)’s stock price was up 11.3% during mid-day trading on Thursday . The company traded as high as $183.66 and last traded at $183.0280. Approximately 675,337 shares changed hands during trading, a decline of 28% from the average daily volume of 942,033 shares. The stock had previously closed at $164.49.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on CRL. TD Cowen decreased their target price on Charles River Laboratories International from $251.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, February 20th. JPMorgan Chase & Co. dropped their price objective on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a research note on Monday, April 13th. Mizuho set a $192.00 price target on shares of Charles River Laboratories International in a report on Friday, May 8th. UBS Group raised their price target on shares of Charles River Laboratories International from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Wednesday, February 25th. Finally, Wall Street Zen downgraded shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Ten investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $207.69.
Charles River Laboratories International Stock Performance
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Thursday, May 7th. The medical research company reported $2.06 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.10. The company had revenue of $995.83 million for the quarter, compared to analysts’ expectations of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The business’s quarterly revenue was up 1.2% compared to the same quarter last year. During the same period last year, the firm posted $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several large investors have recently added to or reduced their stakes in CRL. Invesco Ltd. increased its position in Charles River Laboratories International by 115.8% during the fourth quarter. Invesco Ltd. now owns 2,696,150 shares of the medical research company’s stock worth $537,828,000 after acquiring an additional 1,446,972 shares during the period. Massachusetts Financial Services Co. MA bought a new position in Charles River Laboratories International during the fourth quarter worth about $176,478,000. Victory Capital Management Inc. increased its position in Charles River Laboratories International by 9,938.8% during the fourth quarter. Victory Capital Management Inc. now owns 691,474 shares of the medical research company’s stock worth $137,935,000 after acquiring an additional 684,586 shares during the period. Ameriprise Financial Inc. increased its position in Charles River Laboratories International by 1,491.1% during the third quarter. Ameriprise Financial Inc. now owns 613,604 shares of the medical research company’s stock worth $96,005,000 after acquiring an additional 575,039 shares during the period. Finally, National Bank of Canada FI increased its position in Charles River Laboratories International by 117.7% during the third quarter. National Bank of Canada FI now owns 946,769 shares of the medical research company’s stock worth $148,131,000 after acquiring an additional 511,901 shares during the period. Institutional investors and hedge funds own 98.91% of the company’s stock.
About Charles River Laboratories International
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Articles
- Five stocks we like better than Charles River Laboratories International
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
